IMRN - Immuron Limited
| Previous Close | 3.9500 |
| Open | 3.9500 |
| Bid | 3.9800 x 1000 |
| Ask | 4.0200 x 3000 |
| Day's Range | 3.9500 - 4.0300 |
| 52 Week Range | 2.2310 - 8.4630 |
| Volume | 8,243 |
| Avg. Volume | 65,571 |
| Market Cap | 17.613M |
| Beta (3Y Monthly) | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.93 |
- GlobeNewswire
Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea
Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD)Phase 3 clinical trial of IMM-124E to.
- Simply Wall St.
Could Immuron Limited's (ASX:IMC) Investor Composition Influence The Stock Price?
The big shareholder groups in Immuron Limited (ASX:IMC) have power over the company. Generally speaking, as a company...
- GlobeNewswire
Immuron Receives AUD $0.53M R&D Tax Concession Refund
MELBOURNE, Australia, Nov. 04, 2019 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For October 14, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Synthesis Energy Systems (NASDAQ: SES ) shares ...
- GlobeNewswire
Immuron North American Q1 Sales Up 111% YoY
Key Highlights: First Quarter of FY2020 (Q1) North American sales grew by 111% YoY to $269K AUDQ1 US Travelan® sales increased by +81% YoY to $232K AUDGlobal Immuron sales.
- Benzinga
Immuron Receives $3.7M In Federal Dollars For Traveler's Diarrhea Preventative Therapy Project
The Australian biotech said it has reached an agreement with the U.S. Naval Medical Research Center, or NMRC, to collaborate on the manufacturing and evaluation of a new product designed to protect against traveler's diarrhea caused by campylobacter and ETEC pathogens.
- GlobeNewswire
New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter
NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the funding of a new research agreement with the Naval Medical Research Center (NMRC), Silver Spring, MD, USA. The focus of this new agreement will be to develop a combined Campylobacter and enterotoxigenic E. coli (ETEC)-specific anti-microbial preventative for clinical evaluation.
- Simply Wall St.
Should You Be Concerned About Immuron Limited's (ASX:IMC) Historical Volatility?
Anyone researching Immuron Limited (ASX:IMC) might want to consider the historical volatility of the share price...
- GlobeNewswire
U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea
Key Highlights: Major goal of study was to evaluate Travelan®’s ability to bind and react to a variety of infectious Vibrio cholera strains from Southeast Asia Pathogenic.
- GlobeNewswire
Immuron to Commence Non-Deal Investor Roadshow
MELBOURNE, Australia, Aug. 16, 2019 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
- GlobeNewswire
BriaCell Appoints Richard J. Berman to Board of Directors
BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.
- Simply Wall St.
Some Immuron (ASX:IMC) Shareholders Have Copped A Big 67% Share Price Drop
Investing in stocks comes with the risk that the share price will fall. Anyone who held Immuron Limited (ASX:IMC) over...
- GlobeNewswire
Immuron Reports Results in Severe Alcoholic Hepatitis Clinical Trial
NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the topline results of the clinical study conducted by the TREAT Consortium which was funded by the National Institute of Alcohol Abuse and Alcoholism (NIAAA). The primary objective of the TREAT-003 study was to evaluate the safety and efficacy of IMM-124E at two oral dosage levels as compared with a placebo and provide proof of concept in human subjects for the Mechanism of Action (MoA) in patients with severe alcoholic hepatitis being treated with steroids. The study was conducted at three clinical sites in the USA and supported by a UO1 grant from NIAAA.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For July 17, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Immuron Limited (NASDAQ: IMRN ) shares were ...
- GlobeNewswire
Immuron to Host Investor Webinar on July 18 to Provide Update on Recent Developments
MELBOURNE, Australia, July 17, 2019 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced today that it will participate in an.
- GlobeNewswire
Immuron Prices Underwritten Public Offering of ADSs
MELBOURNE, Australia, July 17, 2019 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
- GlobeNewswire
Immuron Announces Proposed Public Offering of ADSs
NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced that it intends to offer and sell American Depositary Shares, or ADSs in an underwritten public offering. Each ADS represents forty (40) ordinary shares of Immuron. Immuron expects to grant the underwriters a 45-day option to purchase additional ADSs offered in the public offering.
- GlobeNewswire
Immuron North American revenue surges by 52% in FY19
Key Highlights: Immuron FY19 revenue surged by 52% in North America, reaching $1.16M.In the USA, FY19 Travelan® sales exceeded the $1M AUD milestone for the first time and grew.
- GlobeNewswire
Immuron Directors Increase Shareholdings in the Company
MELBOURNE, Australia, June 25, 2019 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company wishes to advise that two of its Directors, Mr Peter.
- GlobeNewswire
Immuron to Commence US Non-Deal Institutional Investor Roadshow
MELBOURNE, Australia, June 19, 2019 -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
- Benzinga
Immuron Rips Higher On Positive Preclinical Results For Travelan
Shares of Australian nano-cap biotech Immuron (NASDAQ: IMRN) rose sharply Wednesday on roughly 250 times average volume. Immuron said the Shigella challenge model – a cooperative R&D project with the U.S. Department of Defense – that assessed the therapeutic potential of Travelan as a preventive treatment of shigellosis or dysentery showed positive results. In an animal study that evaluated 12 juvenile rhesus monkeys - eight treated with Travelan and four with placebo - twice daily for a total of 12 doses over a six-day period, three days prior to the administration of Shigella organisms, it was shown that all Iin the placebo-treated group displayed severe inflammation in different parts of gastrointestinal tract and high levels of inflammatory cytokines in fecal samples.
- GlobeNewswire
US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of.
- Simply Wall St.
How Much Are Immuron Limited (ASX:IMC) Insiders Spending On Buying Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- GlobeNewswire
Immuron Announces the Closing of Public Offering of ADSs
MELBOURNE, Australia, May 30, 2019 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
